Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.10.20.759648

A Pan-Cancer Benchmark of Clustering Strategies for Patient-Specific Gene Regulatory Networks

Abstract

Cancer patients with clinically similar tumors can exhibit substantial differences in disease progression and treatment response. Patient-specific gene regulatory networks (GRNs) may capture regulatory heterogeneity that is not represented by gene expression alone. However, strategies for clustering patients using these high-dimensional networks have not been systematically evaluated and it remains unclear whether clustering based directly on millions of patient-specific regulatory edge weights is computationally feasible at scale. We benchmarked feature-selection and clustering approaches for patient-specific GRNs inferred with PANDA and LIONESS across 9,778 primary tumor samples from 33 cancer types. We compared three data representations: gene expression, gene indegrees summarizing regulatory input to each gene, and complete networks of transcription factor-gene edge weights. Twenty combinations of four feature-selection methods and five clustering algorithms were evaluated using consensus clustering. Performance was assessed based on mean silhouette score, PAC score, concordance, computational time, and memory usage. Standard deviation-based feature selection combined with k-means clustering achieved the strongest overall performance for both GRN-derived representations, with overall scores of 0.997 for edge weights and 0.985 for indegrees, while remaining computationally efficient. Edge-weight- and indegree-derived clusters showed clinical, biological, and prognostic associations that were complementary to those obtained from gene expression. Together, these findings provide a practical framework for network-based cancer patient stratification and highlight the potential of GRN-derived features to reveal clinically relevant tumor heterogeneity beyond gene expression alone.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sarantidis, P., Belova, T., Kuijjer, M.. 2026-10-25. A Pan-Cancer Benchmark of Clustering Strategies for Patient-Specific Gene Regulatory Networks. https://doi.org/10.64898/2026.10.20.759648

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Carrier-Limited Release Risk in Electrospun Nanofibers for Regenerative Endodontics: Constraint Discovery from 25 Formulations

Regenerative endodontics needs an intracanal carrier that keeps disinfecting across a dressing interval that clinicians schedule at one to four weeks, without harming the stem cells that rebuild the pulp. We ask what one completed 25-formulation electrospinning campaign of poly(vinylpyrrolidone) (PVP) fibers carrying metronidazole, ciprofloxacin, minocycline and Ca(OH)2 can decide, and use machine learning for constraint discovery and decision support rather than as a new predictor. After an audit against the source thesis, logistic regression predicts fine-fiber formation at 96% leave-one-out accuracy, but a one-threshold rule does as well, the gain over the 80% majority baseline is not significant (exact McNemar p = 0.125), and accuracy falls to 84% when mixture loading is encoded per component. Diameter models interpolate within formulation families (ridge MAE 193 nm, 95% CI 96 to 317 nm) and fail across them (R^2 < 0). Because the campaign never measured release, we assemble a same-drug, cross-carrier evidence table: 17 bounded metronidazole and ciprofloxacin observations from seven studies, with two-sided censoring. Water-soluble carriers (PVP, PVA) completed release within 80 h (PVP within 8 h); no water-insoluble monolithic carrier reached 90% within its observation window, releasing 1.5 to 50%; both within-study comparisons separate at matched loading; and blend, core-shell and thick-mat architectures released over 3 to 28 days. The PVP mats therefore carry a carrier-limited release risk, not a proven ceiling, and one dissolution experiment can confirm or overturn it. A censoring-aware screen keeps three necessarily and one possibly nondominated formulation, and fixed-budget replays show that uncertainty sampling finds failed formulations sooner, except the one it is confidently wrong about.

bioinformatics↗

CellMethMarker provides an integrated database of human cell- and tissue-type-specific DNA methylation markers

Cell- and tissue-type-specific DNA methylation markers provide epigenetic signatures of cellular identity and are widely used to infer cellular origin from bulk and single-cell methylomes. Existing resources mainly emphasize disease-associated biomarkers, methylome atlases, genomic annotations or RNA-based cell markers, leaving an unmet need for an integrated region-level resource dedicated to such markers. Here we present CellMethMarker (http://gu-zhanglab.hfcas.ac.cn/CellMethMarker), a curated database integrating 347,514 de novo markers derived from uniformly processed whole-genome and reduced-representation bisulfite sequencing datasets, 2,203,507 literature-derived marker records and harmonized metadata for 2,810 samples. CellMethMarker enables cell- and tissue-centered marker retrieval, coordinate-based search, genome-browser visualization, interactive methylation analysis and data download. In an independent single-cell methylome atlas, these markers recover the expected cell-type-associated methylation patterns, and a platform-matched reference built from them lowers the mean deconvolution error from 0.365 to 0.144. CellMethMarker therefore links region-level DNA methylation variation to cellular identity and supports methylome-based cell-type annotation and deconvolution.

bioinformatics↗

IG-28 enables identification and quantification of high-confidence isoforms from large bulk and single-cell full-length cDNA datasets

The technology to sequence full-length transcriptomes from bulk and single-cell samples has rapidly advanced. As a result, full-length cDNA datasets now reach billions of reads in size which is beyond the capability of most established isoform identification tools. Here, we introduce IG-28 which addresses this challenge with its capability to process and analyze large fl-cDNA datasets fast and using minimal computational resources. In contrast to its predecessor Mandalorion, IG-28 is not limited to bulk fl-cDNA but is capable of parsing, processing, and analyzing single-cell fl-cDNA datasets. It does so in a lightweight, flexible manner, integrating seamlessly with established scRNA-seq analysis workflows. We benchmarked IG-28 against a variety of established and new isoform identification tools using several bulk and a complex single-cell fl-cDNA dataset and found that IG-28 consistently outperformed the other tools by identifying high-confidence public isoforms.

bioinformatics↗